Week 10 is where TRT stops being a prescription and starts being a feedback loop. The first 10 weeks were the open-loop phase: you picked a dose, you ran it, you watched. Now the labs come back, the symptoms have either resolved or they haven't, and the protocol either earns its place or it changes. Most men get this wrong by reading total testosterone, seeing a big number, and declaring victory. The practitioner corpus is unanimous on this: total T on TRT doesn't matter on its own. What matters is the six-marker constellation — free T, SHBG, estradiol, hematocrit, LH/FSH (if fertility is in play), and the symptom delta. Week 10 is when you read all six and decide which of three scenarios you're in.
The biology underneath this is straightforward. Exogenous testosterone shuts down the HPG axis at the hypothalamus — GnRH stops pulsing, LH and FSH collapse, the Leydig cells go quiet, and intratesticular testosterone drops by ~95%. The serum total comes from the injection. The serum free fraction depends on SHBG, which the liver titrates against thyroid status, insulin sensitivity, and oral androgen exposure. Estradiol comes from aromatization of the exogenous T at adipose and at the testes themselves. Hematocrit climbs because androgens stimulate erythropoietin and suppress hepcidin — more red cells, thicker blood, and at the high end, real stroke risk. Each of these moves on its own clock, and the week-10 labs are the first time you see the whole system at a new steady state.
Scenario A — Clear response
You're in scenario A when free testosterone is in the upper third of the reference range, estradiol sits in the 20–30 pg/mL window (some practitioners run up to 40 with no symptoms), hematocrit is under 52%, and the symptoms you started TRT for — morning erections, training recovery, mental drive, sleep quality, libido — have all moved in the direction you wanted. Total T can be anywhere from 800 to 1200+ ng/dL; the number doesn't matter if free T is right and you feel right. The practitioner consensus is that symptom resolution trumps lab numbers when the two disagree, but in scenario A they agree.
The protocol move here is the smallest one: don't change anything. Re-pull full labs at the six-month mark, not before. Weekly clinic check-ins on someone in scenario A are a revenue model, not medicine — the corpus is explicit that you do not need bloodwork "every seven minutes" once you're dialed in. Maintain the current dose, maintain the current injection cadence, maintain any ancillary you're already on (gonadorelin for testicular preservation, low-dose anastrozole if E2 was a problem at start). The only thing that earns a mid-cycle re-pull is a new symptom.
Scenario B — Partial response
This is the most common week-10 outcome and the one that demands the most decoding. Partial response means the labs and symptoms disagree, or some markers landed and others didn't. The four common partial-response patterns and their corresponding protocol moves:
| Pattern | Marker signature | Next protocol move | Evidence Tier |
|---|---|---|---|
| Total T high, free T low | TT 900+, free T bottom-third, SHBG >45 | Hold dose; address SHBG upstream (insulin, thyroid, oral exposures). Some practitioners run boron 6–10 mg/day; corpus thin on dosing — track and report. | Expert 🟢 |
| E2 elevated | E2 >50 pg/mL on sensitive assay, water retention, nipple sensitivity | Anastrozole 0.25–0.5 mg oral, 2x/week, titrate to E2. Do NOT crash E2 — joint pain and mood collapse. | Expert 🟢 |
| Hematocrit creeping | Hct 52–54%, no symptoms yet | Reduce TRT dose ~20% OR increase injection frequency (smaller doses, more often). Therapeutic phlebotomy is the backstop, not the first move. | Clinical 🔵 |
| LH/FSH still suppressed on TRT+HCG | LH <0.5, FSH <1.0, HCG already in stack | HCG dose may be too low. Corpus describes 250–500 IU added to TRT for fertility preservation; titrate up before declaring HCG a failure. Kisspeptin-10 (50–100 mcg SubQ daily) is the experimental upstream option. | Expert 🟢 / Experimental 🟣 |
The tempting move in scenario B is to add compounds. The disciplined move is usually to subtract or adjust one variable, then re-test at six weeks. Changing three things at once gives you a result you can't read. Pick the marker that's most out of range, address it, re-pull at week 16.
One specific pattern from the corpus deserves its own callout: total T at the top of the range with free T at the bottom and SHBG climbing. This is not a TRT failure. This is the liver responding to either undertreated thyroid (TSH >2.5), insulin resistance (fasting glucose >100, fasting insulin >8), or an oral androgen exposure you forgot you were running. Raising the TRT dose to chase free T in this state will spike E2 and hematocrit without moving the free fraction. Fix the upstream driver first.
Scenario C — No response
Scenario C is rare and serious. Free T is optimized, E2 is in range, hematocrit is fine, and you feel the same as the day you started — or worse. The corpus is clear on what's happening here: the testosterone deficiency was either not the primary problem, or it was downstream of something else.
The differential at this point splits three ways:
- Adrenal/cortisol axis dysfunction. Low DHEA-S, flat diurnal cortisol curve, persistent fatigue despite optimized T. The corpus describes pregnenolone 25–50 mg oral daily as monotherapy here — the "mother hormone" the body converts downstream — sometimes layered with Thymosin Alpha-1 1.6 mg SubQ 2x/week if there's an immune-exhaustion overlay.
- Thyroid suppression. TSH >2.5, fT3 in the bottom third, reverse T3 climbing. Optimizing T while leaving fT3 floor-level is a known no-response pattern. Address the thyroid before re-litigating the TRT dose.
- Metabolic / mitochondrial. Fasting glucose >100, fasting insulin >8, triglyceride-to-HDL ratio above 2. The corpus points to MOTS-c and (in the right candidate) retatrutide here. Testosterone won't fix mitochondrial inefficiency on its own.
A small subset of scenario C cases is genuinely TRT-refractory — the receptor sensitivity is off, the SHBG is locked in a range that won't move, or the symptoms were never androgen-driven to begin with. The decision tree at that point is to stop escalating TRT and look sideways.
What's NOT happening yet at week 10
- The full hematocrit response. Erythrocytosis can keep climbing through month 4–6 even on a stable dose. A week-10 Hct of 49% is not "safe forever" — it's a checkpoint.
- HPG axis recovery if you're on TRT-only without HCG or gonadorelin. LH and FSH won't come back on their own while exogenous T is in the system. Don't read suppressed gonadotropins at week 10 as a problem to solve unless fertility is on the table.
- Final SHBG settling. SHBG often takes 12–16 weeks to find its new floor on TRT. A week-10 SHBG read is provisional.
- Bone density, lipid restructuring, and body composition. These are 6-month markers, not 10-week markers. Don't grade the protocol on them yet.
The labs describe the system. The symptoms describe you. When they disagree, the corpus says trust the symptoms — and re-pull in six weeks.